{"transactions":[{"id":729577,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-23T23:51:55.000Z","date":"2026-06-20","kind":"exercise","planned":false,"acquired":false,"shares":18880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18880},"source":{"system":"sec-edgar","filing":"0001104659-26-076925","document":"tm2618639-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926076925/tm2618639-4_4seq1.xml","form_type":"4"}},{"id":729576,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-23T23:51:55.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":14180,"derivative":{"underlying":"Common Stock","underlying_shares":14180},"source":{"system":"sec-edgar","filing":"0001104659-26-076925","document":"tm2618639-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926076925/tm2618639-4_4seq1.xml","form_type":"4"}},{"id":729575,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T23:51:55.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":21270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":21270,"derivative":{"exercise_price":9.13,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":21270},"source":{"system":"sec-edgar","filing":"0001104659-26-076925","document":"tm2618639-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926076925/tm2618639-4_4seq1.xml","form_type":"4"}},{"id":729574,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-23T23:51:55.000Z","date":"2026-06-20","kind":"exercise","planned":false,"acquired":true,"shares":18880,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."}],"balance_after":79770,"source":{"system":"sec-edgar","filing":"0001104659-26-076925","document":"tm2618639-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926076925/tm2618639-4_4seq1.xml","form_type":"4"}},{"id":731929,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:07:32.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":39715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":39715,"derivative":{"exercise_price":5.67,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":39715},"source":{"system":"sec-edgar","filing":"0001219871-26-000003","document":"wk-form4_1781813248.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000121987126000003/wk-form4_1781813248.xml","form_type":"4"}},{"id":731928,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:07:32.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":26455,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock units (\"RSUs\"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":3349655,"source":{"system":"sec-edgar","filing":"0001219871-26-000003","document":"wk-form4_1781813248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000121987126000003/wk-form4_1781813248.xml","form_type":"4"}},{"id":731927,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:07:32.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":20282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":3323200,"source":{"system":"sec-edgar","filing":"0001219871-26-000003","document":"wk-form4_1781813248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000121987126000003/wk-form4_1781813248.xml","form_type":"4"}},{"id":887945,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-24T02:01:11.000Z","date":"2026-02-20","kind":"purchase","planned":false,"acquired":true,"shares":333333,"price":5.839,"value":1946331.387,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.67 per share to $6.00 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":3302918,"source":{"system":"sec-edgar","filing":"0001610717-26-000066","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000161071726000066/form4.xml","form_type":"4"}},{"id":946349,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":56.5,"underlying":"Common Stock","underlying_shares":2200},"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946348,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":734,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":216,"underlying":"Common Stock","underlying_shares":734},"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946347,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":90.5,"underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946346,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":740,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":161,"underlying":"Common Stock","underlying_shares":740},"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946345,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1002,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":372.5,"underlying":"Common Stock","underlying_shares":1002},"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946344,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":181,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":527.25,"underlying":"Common Stock","underlying_shares":181},"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946343,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":368,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":572.5,"underlying":"Common Stock","underlying_shares":368},"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946342,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":788,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":134,"underlying":"Common Stock","underlying_shares":788},"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946341,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":107.75,"underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946340,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1011,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":107.75,"underlying":"Common Stock","underlying_shares":1011},"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946339,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":306.75,"underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946338,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":264,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":434.75,"underlying":"Common Stock","underlying_shares":264},"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946337,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2460,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."}],"balance_after":0,"derivative":{"exercise_price":9.0775,"underlying":"Common Stock","underlying_shares":2460},"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946336,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"other","planned":false,"acquired":false,"shares":383,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities were held directly by the David Mott Declaration of Trust dated May 31, 2001, as amended (the \"Mott Trust\"). The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Act of 1934, as amended, or otherwise of such portion of the securities held by the Mott Trust in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":946335,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:39:24.000Z","date":"2026-01-06","kind":"other","planned":false,"acquired":false,"shares":23546,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-001368","document":"tm261736-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001368/tm261736-2_4seq1.xml","form_type":"4"}},{"id":1103165,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-24T22:40:20.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":18884,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":18884,"derivative":{"underlying":"Common Stock","underlying_shares":18884},"source":{"system":"sec-edgar","filing":"0001104659-25-062195","document":"tm2518838-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925062195/tm2518838-5_4seq1.xml","form_type":"4"}},{"id":1103164,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-24T22:40:20.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":28326,"price":6.42,"value":181852.92,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 20, 2024 grant date subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":28326,"derivative":{"exercise_price":6.42,"expiration_date":"2035-06-20","underlying":"Common Stock","underlying_shares":28326},"source":{"system":"sec-edgar","filing":"0001104659-25-062195","document":"tm2518838-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925062195/tm2518838-5_4seq1.xml","form_type":"4"}},{"id":1103634,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-24T00:40:41.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":54059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":54059,"derivative":{"exercise_price":3.61,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":54059},"source":{"system":"sec-edgar","filing":"0001628280-25-032727","document":"wk-form4_1750725635.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025032727/wk-form4_1750725635.xml","form_type":"4"}},{"id":1103633,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T00:40:41.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":41551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock units (\"RSUs\"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof.  The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":2969585,"source":{"system":"sec-edgar","filing":"0001628280-25-032727","document":"wk-form4_1750725635.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025032727/wk-form4_1750725635.xml","form_type":"4"}},{"id":1103632,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T00:40:41.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":31163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":2928034,"source":{"system":"sec-edgar","filing":"0001628280-25-032727","document":"wk-form4_1750725635.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025032727/wk-form4_1750725635.xml","form_type":"4"}},{"id":1106162,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-19T01:28:07.000Z","date":"2025-06-16","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":3.6294,"value":725880.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Transaction was executed in multiple trades in prices ranging from $3.57 to $3.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":2896871,"source":{"system":"sec-edgar","filing":"0001628280-25-032226","document":"wk-form4_1750296481.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025032226/wk-form4_1750296481.xml","form_type":"4"}},{"id":1112401,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-06-14T01:39:26.000Z","date":"2025-06-12","kind":"exercise","planned":false,"acquired":false,"shares":10420,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2025-06-12","expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":10420},"source":{"system":"sec-edgar","filing":"0001593968-25-000758","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396825000758/primary_01.xml","form_type":"4"}},{"id":1112400,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-14T01:39:26.000Z","date":"2025-06-12","kind":"exercise","planned":false,"acquired":true,"shares":10420,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":60890,"source":{"system":"sec-edgar","filing":"0001593968-25-000758","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396825000758/primary_01.xml","form_type":"4"}},{"id":1111477,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:55:20.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":61500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2026 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":61500,"derivative":{"exercise_price":0.36,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":61500},"source":{"system":"sec-edgar","filing":"0001104659-25-059425","document":"tm2517941-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925059425/tm2517941-2_4seq1.xml","form_type":"4"}},{"id":1114819,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-12T01:40:28.000Z","date":"2025-06-09","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":3.6863,"value":737260.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Transaction was executed in multiple trades in prices ranging from $3.61 to $3.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":2696871,"source":{"system":"sec-edgar","filing":"0001628280-25-030848","document":"wk-form4_1749692421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025030848/wk-form4_1749692421.xml","form_type":"4"}},{"id":1142454,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T21:02:11.000Z","date":"2025-05-15","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":3.2912,"value":329120.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Transaction was executed in multiple trades in prices ranging from $3.22 to $3.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":2496871,"source":{"system":"sec-edgar","filing":"0001628280-25-026573","document":"wk-form4_1747688522.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025026573/wk-form4_1747688522.xml","form_type":"4"}},{"id":1159042,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-06T00:22:23.000Z","date":"2025-05-02","kind":"purchase","planned":false,"acquired":true,"shares":381377,"price":4.224,"value":1610936.448,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Transaction was executed in multiple trades in prices ranging from $3.745 to $4.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":2396871,"source":{"system":"sec-edgar","filing":"0001628280-25-022357","document":"wk-form4_1746490936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025022357/wk-form4_1746490936.xml","form_type":"4"}},{"id":1242790,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-27T00:21:25.000Z","date":"2025-02-24","kind":"purchase","planned":false,"acquired":true,"shares":77729,"price":5.0012,"value":388738.2748,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transaction was executed in multiple trades in prices ranging from $4.90 to $5.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":2015494,"source":{"system":"sec-edgar","filing":"0001628280-25-008296","document":"wk-form4_1740615678.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025008296/wk-form4_1740615678.xml","form_type":"4"}},{"id":1297432,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-22T22:25:52.000Z","date":"2025-01-21","kind":"purchase","planned":false,"acquired":true,"shares":199000,"price":4.9883,"value":992671.7,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":1937765,"source":{"system":"sec-edgar","filing":"0001628280-25-002226","document":"wk-form4_1737584745.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025002226/wk-form4_1737584745.xml","form_type":"4"}},{"id":1320933,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-27T22:57:10.000Z","date":"2024-12-26","kind":"exercise","planned":false,"acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":0.55,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001628280-24-052533","document":"wk-form4_1735340223.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024052533/wk-form4_1735340223.xml","form_type":"4"}},{"id":1320932,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-27T22:57:10.000Z","date":"2024-12-26","kind":"exercise","planned":false,"acquired":true,"shares":100000,"price":0.55,"value":55000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":1738765,"source":{"system":"sec-edgar","filing":"0001628280-24-052533","document":"wk-form4_1735340223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024052533/wk-form4_1735340223.xml","form_type":"4"}},{"id":1322760,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T22:59:18.000Z","date":"2024-12-19","kind":"purchase","planned":false,"acquired":true,"shares":213300,"price":4.6722,"value":996580.26,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Transaction was executed in multiple trades in prices ranging from $4.55 to $4.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":1638765,"source":{"system":"sec-edgar","filing":"0001628280-24-052363","document":"wk-form4_1734994751.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024052363/wk-form4_1734994751.xml","form_type":"4"}},{"id":1365037,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-14T21:26:52.000Z","date":"2024-11-13","kind":"purchase","planned":false,"acquired":true,"shares":215868,"price":4.6167,"value":996597.7956,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Transaction was executed in multiple trades in prices ranging from $4.435 to $4.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":1425465,"source":{"system":"sec-edgar","filing":"0001628280-24-047919","document":"wk-form4_1731619603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024047919/wk-form4_1731619603.xml","form_type":"4"}},{"id":1465589,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-07-01T21:04:22.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1583214,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":1583214,"derivative":{"exercise_price":0.16,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":1583214},"source":{"system":"sec-edgar","filing":"0001104659-24-076897","document":"tm2418639-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000110465924076897/tm2418639-7_4seq1.xml","form_type":"4"}},{"id":1477191,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T22:47:24.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":40243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":40243,"derivative":{"exercise_price":6.35,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":40243},"source":{"system":"sec-edgar","filing":"0001628280-24-028594","document":"wk-form4_1718664437.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024028594/wk-form4_1718664437.xml","form_type":"4"}},{"id":1477190,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-17T22:47:24.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":17322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":1209597,"source":{"system":"sec-edgar","filing":"0001628280-24-028594","document":"wk-form4_1718664437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024028594/wk-form4_1718664437.xml","form_type":"4"}},{"id":1479721,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2024-06-14T20:06:39.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":10420,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10420,"derivative":{"exercise_price":0,"exercise_date":"2025-06-12","expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":10420},"source":{"system":"sec-edgar","filing":"0001593968-24-000861","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396824000861/primary_01.xml","form_type":"4"}},{"id":1479720,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:06:39.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":15630,"price":15.86,"value":247891.8,"ownership":{"direct":true},"balance_after":15630,"derivative":{"exercise_price":15.86,"exercise_date":"2025-06-12","expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":15630},"source":{"system":"sec-edgar","filing":"0001593968-24-000861","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396824000861/primary_01.xml","form_type":"4"}},{"id":1479719,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2024-06-14T20:06:39.000Z","date":"2024-06-12","kind":"exercise","planned":false,"acquired":false,"shares":6670,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2024-06-12","expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":6670},"source":{"system":"sec-edgar","filing":"0001593968-24-000861","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396824000861/primary_01.xml","form_type":"4"}},{"id":1479718,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-14T20:06:39.000Z","date":"2024-06-12","kind":"exercise","planned":false,"acquired":true,"shares":6670,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50470,"source":{"system":"sec-edgar","filing":"0001593968-24-000861","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000159396824000861/primary_01.xml","form_type":"4"}},{"id":1481973,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-12T20:53:31.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":55000,"derivative":{"exercise_price":2.26,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-24-070898","document":"tm2417031-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924070898/tm2417031-5_4seq1.xml","form_type":"4"}},{"id":1687622,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-04T21:11:00.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":8810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of fully vested shares of stock rather than cash.  The shares were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as amended, in lieu of retainer fees of $20,000 for the quarter ended December 31, 2023.  The number of shares issued was based on the closing price per share of the Issuer's common stock on January 2, 2024, which was $2.27."}],"balance_after":588694,"source":{"system":"sec-edgar","filing":"0001104659-24-001358","document":"tm241899-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924001358/tm241899-1_4seq1.xml","form_type":"4"}},{"id":1765220,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-04T20:26:09.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":15873,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of fully vested shares of stock rather than cash.  The shares were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $20,000 for the quarter ended September 30, 2023.  The number of shares issued was based on the closing price per share of the Issuer's common stock on October 2, 2023, which was $1.26."}],"balance_after":579884,"source":{"system":"sec-edgar","filing":"0001104659-23-106831","document":"tm2327613-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923106831/tm2327613-1_4seq1.xml","form_type":"4"}},{"id":1833756,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-06T20:18:11.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":6079,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of fully vested shares of stock rather than cash.  The shares were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $20,000 for the quarter ended June 30, 2023.  The number of shares issued was based on the closing price per share of the Issuer's common stock on June 30, 2023, which was $3.29."}],"balance_after":564011,"source":{"system":"sec-edgar","filing":"0001104659-23-078749","document":"tm2320657-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923078749/tm2320657-1_4seq1.xml","form_type":"4"}},{"id":1839457,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2023-07-03T21:01:34.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":1462927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.12 based on an exchange rate of $U.S. 1.270841 to GBP1.00. The actual exercise price will be the pounds sterling amount"}],"balance_after":1462927,"derivative":{"exercise_price":0.16,"exercise_date":"2024-07-03","expiration_date":"2033-07-03","underlying":"Ordinary Shares","underlying_shares":1462927},"source":{"system":"sec-edgar","filing":"0001104659-23-077664","document":"tm2320409-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000110465923077664/tm2320409-2_4seq1.xml","form_type":"4"}},{"id":1851963,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T22:29:07.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":49237,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":49237,"derivative":{"exercise_price":3.92,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":49237},"source":{"system":"sec-edgar","filing":"0001628280-23-022554","document":"wk-form4_1686954538.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023022554/wk-form4_1686954538.xml","form_type":"4"}},{"id":1851962,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T22:29:07.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":25510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":1192275,"source":{"system":"sec-edgar","filing":"0001628280-23-022554","document":"wk-form4_1686954538.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023022554/wk-form4_1686954538.xml","form_type":"4"}},{"id":1857762,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-13T20:47:44.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":6670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":6670,"derivative":{"underlying":"Common Stock","underlying_shares":6670},"source":{"system":"sec-edgar","filing":"0001209191-23-036757","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123036757/doc4.xml","form_type":"4"}},{"id":1857761,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T20:47:44.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":7710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One hundred percent (100%) of the shares subject to this option grant under the Plan will vest one (1) year from the June 12, 2023 grant date (the \"Grant Date\") subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":7710,"derivative":{"exercise_price":7.78,"exercise_date":"2024-06-12","expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":7710},"source":{"system":"sec-edgar","filing":"0001209191-23-036757","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123036757/doc4.xml","form_type":"4"}},{"id":1857760,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-13T20:47:44.000Z","date":"2023-06-10","kind":"exercise","planned":false,"acquired":false,"shares":3100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\"), vested on the first anniversary of the June 10, 2022 grant date subject to continued service on the Company's Board of Directors through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\"), vested on the first anniversary of the June 10, 2022 grant date subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3100},"source":{"system":"sec-edgar","filing":"0001209191-23-036757","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123036757/doc4.xml","form_type":"4"}},{"id":1857759,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-13T20:47:44.000Z","date":"2023-06-10","kind":"exercise","planned":false,"acquired":true,"shares":3100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."}],"balance_after":43800,"source":{"system":"sec-edgar","filing":"0001209191-23-036757","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919123036757/doc4.xml","form_type":"4"}},{"id":1858669,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:15:51.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":18355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":18355,"derivative":{"exercise_price":8.64,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":18355},"source":{"system":"sec-edgar","filing":"0001104659-23-070358","document":"tm2318463-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923070358/tm2318463-3_4seq1.xml","form_type":"4"}},{"id":1858668,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T20:15:51.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":14467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award.  Each RSU represents the contingent right to receive one share of Common Stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":557932,"source":{"system":"sec-edgar","filing":"0001104659-23-070358","document":"tm2318463-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923070358/tm2318463-3_4seq1.xml","form_type":"4"}},{"id":1924926,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-05T21:14:37.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":4866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of fully vested shares of stock rather than cash. The shares were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $20,000 for the quarter ended March 31, 2023. The number of shares issued was based on the closing price per share of the Issuer's common stock on March 31, 2023, which was $4.11."}],"balance_after":543465,"source":{"system":"sec-edgar","filing":"0001104659-23-042242","document":"tm2311858-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923042242/tm2311858-3_4seq1.xml","form_type":"4"}},{"id":2111990,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-17T21:07:16.000Z","date":"2022-11-17","kind":"purchase","acquired":true,"shares":567000,"price":1.7648,"value":1000641.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.65 per share to $1.78 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":1166765,"source":{"system":"sec-edgar","filing":"0001567619-22-020554","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761922020554/doc1.xml","form_type":"4"}},{"id":2183879,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-08-16T22:59:01.000Z","date":"2022-08-12","kind":"other","acquired":false,"shares":106959,"ownership":{"direct":false,"nature":"See Note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects disposition of shares of common stock of the Issuer (\"Shares\") in connection with that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. (\"Merger Sub\"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the \"Cash Consideration\"), plus (ii) one (1) contractual contingent value right per Share (\"CVR\"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the \"Effective Time\"), each Share held by the Reporting Person was converted into the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of shares of common stock of the Issuer (\"Shares\") in connection with that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. (\"Merger Sub\"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the \"Cash Consideration\"), plus (ii) one (1) contractual contingent value right per Share (\"CVR\"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the \"Effective Time\"), each Share held by the Reporting Person was converted into the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly held by the David Mott Declaration of Trust dated May 31, 2001 as amended (the \"Mott Trust\"). The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the Mott Trust shares in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-028869","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000089924322028869/doc4.xml","form_type":"4"}},{"id":2183878,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-08-16T22:59:01.000Z","date":"2022-08-12","kind":"disposition_to_issuer","acquired":false,"shares":8994,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects disposition of restricted stock units (\"RSUs\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition of restricted stock units (\"RSUs\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-028869","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000089924322028869/doc4.xml","form_type":"4"}},{"id":2183877,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-08-16T22:59:01.000Z","date":"2022-08-12","kind":"other","acquired":false,"shares":215494,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects disposition of shares of common stock of the Issuer (\"Shares\") in connection with that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. (\"Merger Sub\"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the \"Cash Consideration\"), plus (ii) one (1) contractual contingent value right per Share (\"CVR\"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the \"Effective Time\"), each Share held by the Reporting Person was converted into the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of shares of common stock of the Issuer (\"Shares\") in connection with that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. (\"Merger Sub\"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the \"Cash Consideration\"), plus (ii) one (1) contractual contingent value right per Share (\"CVR\"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the \"Effective Time\"), each Share held by the Reporting Person was converted into the Offer Price."}],"balance_after":8994,"source":{"system":"sec-edgar","filing":"0000899243-22-028869","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000089924322028869/doc4.xml","form_type":"4"}},{"id":2214195,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-07-05T21:06:31.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":16156,"price":1.47,"value":23749.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued to the Reporting Person pursuant to his election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $23,750 for Board services for the second fiscal quarter of 2022. The shares were issued on the last day of the second fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter."}],"balance_after":224488,"source":{"system":"sec-edgar","filing":"0000899243-22-025018","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000089924322025018/doc4.xml","form_type":"4"}},{"id":2216870,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2022-07-01T21:00:27.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":1000439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00.  The actual exercise price will be the pounds sterling amount"}],"balance_after":1000439,"derivative":{"exercise_price":0.28,"exercise_date":"2023-07-01","expiration_date":"2032-07-01","underlying":"Ordinary Shares","underlying_shares":1000439},"source":{"system":"sec-edgar","filing":"0001104659-22-076894","document":"tm2220260-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000110465922076894/tm2220260-1_4seq1.xml","form_type":"4"}},{"id":2226056,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-22T00:49:53.000Z","date":"2022-06-17","kind":"exercise","acquired":false,"shares":700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 17, 2021 grant date subject to continued service on the Company's Board of Directors through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 17, 2021 grant date subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":700},"source":{"system":"sec-edgar","filing":"0001209191-22-038596","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122038596/doc4.xml","form_type":"4"}},{"id":2226055,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-22T00:49:53.000Z","date":"2022-06-17","kind":"exercise","acquired":true,"shares":700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Novavax, Inc. (the \"Company\") common stock."}],"balance_after":40700,"source":{"system":"sec-edgar","filing":"0001209191-22-038596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122038596/doc4.xml","form_type":"4"}},{"id":2225302,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-21T20:51:26.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":0.548,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001567619-22-013204","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761922013204/doc1.xml","form_type":"4"}},{"id":2225301,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-21T20:51:26.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":182481,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein."}],"balance_after":599765,"source":{"system":"sec-edgar","filing":"0001567619-22-013204","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761922013204/doc1.xml","form_type":"4"}},{"id":2233202,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-14T21:09:51.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":3100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Company common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":3100,"derivative":{"underlying":"Common Stock","underlying_shares":3100},"source":{"system":"sec-edgar","filing":"0001209191-22-036756","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122036756/doc4.xml","form_type":"4"}},{"id":2233201,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-14T21:09:51.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the \"Company\") Amended and Restated 2015 Stock Incentive Plan, as amended (the \"Plan\") will vest one (1) year from the June 10, 2022 grant date (the \"Grant Date\") subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":4600,"derivative":{"exercise_price":40.62,"exercise_date":"2023-06-10","expiration_date":"2032-06-10","underlying":"Common Stock","underlying_shares":4600},"source":{"system":"sec-edgar","filing":"0001209191-22-036756","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919122036756/doc4.xml","form_type":"4"}},{"id":2235785,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T20:19:05.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2023 Annual Meeting of Stockholders of Mersana Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":3.62,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-22-070140","document":"tm2218135-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922070140/tm2218135-3_4seq1.xml","form_type":"4"}},{"id":2244763,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-04T00:17:36.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant."}],"balance_after":8500,"derivative":{"exercise_price":1.07,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-22-034382","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919122034382/doc4.xml","form_type":"4"}},{"id":2263334,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-19T20:26:18.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":41006,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on May 17, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full."}],"balance_after":41006,"derivative":{"exercise_price":0.56,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":41006},"source":{"system":"sec-edgar","filing":"0000899243-22-018829","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000089924322018829/doc4.xml","form_type":"4"}},{"id":2263333,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-05-19T20:26:18.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":8994,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 8,994 restricted stock units (\"RSUs\") granted on May 17, 2022, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full."}],"balance_after":208332,"source":{"system":"sec-edgar","filing":"0000899243-22-018829","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000089924322018829/doc4.xml","form_type":"4"}},{"id":2310930,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-04-01T21:30:41.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":20653,"price":1.15,"value":23750.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued to the Reporting Person pursuant to his election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $23,750 for Board services for the first fiscal quarter of 2022.  The shares were issued on the last day of the first fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter."}],"balance_after":199338,"source":{"system":"sec-edgar","filing":"0000899243-22-013153","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000089924322013153/doc4.xml","form_type":"4"}},{"id":2378634,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-24T00:12:38.000Z","date":"2022-02-23","kind":"purchase","acquired":true,"shares":35257,"price":1.46,"value":51475.22,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Mott undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market purchases reported on this line occurred at a weighted average price of $1.46 (range $1.39 to $1.50)."}],"balance_after":229224,"source":{"system":"sec-edgar","filing":"0001209191-22-012399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919122012399/doc4.xml","form_type":"4"}},{"id":2378633,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-24T00:12:38.000Z","date":"2022-02-22","kind":"purchase","acquired":true,"shares":65817,"price":1.56,"value":102674.52,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Mott undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market purchases reported on this line occurred at a weighted average price of $1.56 (range $1.44 to $1.60)."}],"balance_after":193967,"source":{"system":"sec-edgar","filing":"0001209191-22-012399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919122012399/doc4.xml","form_type":"4"}},{"id":2378632,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-24T00:12:38.000Z","date":"2022-02-18","kind":"purchase","acquired":true,"shares":50398,"price":1.3,"value":65517.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Open market purchases reported on this line occurred at a weighted average price of $1.30 (range $1.23 to $1.38)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Mott undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price."}],"balance_after":128150,"source":{"system":"sec-edgar","filing":"0001209191-22-012399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919122012399/doc4.xml","form_type":"4"}},{"id":2388559,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-18T00:21:50.000Z","date":"2022-02-17","kind":"purchase","acquired":true,"shares":14595,"price":1.17,"value":17076.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Mott undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market purchases reported on this line occurred at a weighted average price of $1.17 (range $1.15 to $1.21)."}],"balance_after":77752,"source":{"system":"sec-edgar","filing":"0001209191-22-011049","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919122011049/doc4.xml","form_type":"4"}},{"id":2388558,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-18T00:21:50.000Z","date":"2022-02-16","kind":"purchase","acquired":true,"shares":11779,"price":1.2,"value":14134.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Mott undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market purchases reported on this line occurred at a weighted average price of $1.20 (range $1.17 to $1.23)."}],"balance_after":63157,"source":{"system":"sec-edgar","filing":"0001209191-22-011049","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919122011049/doc4.xml","form_type":"4"}},{"id":2388557,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-18T00:21:50.000Z","date":"2022-02-15","kind":"purchase","acquired":true,"shares":19552,"price":1.2,"value":23462.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Open market purchases reported on this line occurred at a weighted average price of $1.20 (range $1.16 to $1.26)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Mott undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price."}],"balance_after":51378,"source":{"system":"sec-edgar","filing":"0001209191-22-011049","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919122011049/doc4.xml","form_type":"4"}},{"id":2398045,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-14T22:02:52.000Z","date":"2022-02-14","kind":"purchase","acquired":true,"shares":8500,"price":1.18,"value":10030.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Mott undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market purchases reported on this line occurred at a weighted average price of $1.18 (range $1.15 to $1.20)."}],"balance_after":31826,"source":{"system":"sec-edgar","filing":"0001209191-22-009391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919122009391/doc4.xml","form_type":"4"}},{"id":2398044,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-14T22:02:52.000Z","date":"2022-02-11","kind":"purchase","acquired":true,"shares":14573,"price":1.23,"value":17924.79,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Mott undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market purchases reported on this line occurred at a weighted average price of $1.23 (range $1.17 to $1.29)."}],"balance_after":23326,"source":{"system":"sec-edgar","filing":"0001209191-22-009391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919122009391/doc4.xml","form_type":"4"}},{"id":2398043,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-14T22:02:52.000Z","date":"2022-02-10","kind":"purchase","acquired":true,"shares":8753,"price":1.29,"value":11291.37,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Open market purchases reported on this line occurred at a weighted average price of $1.29 (range $1.26 to $1.33)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Mr. Mott undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price."}],"balance_after":8753,"source":{"system":"sec-edgar","filing":"0001209191-22-009391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919122009391/doc4.xml","form_type":"4"}},{"id":2443723,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T22:07:01.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":18518,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2022."}],"balance_after":18518,"derivative":{"exercise_price":6.44,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":18518},"source":{"system":"sec-edgar","filing":"0001104659-22-001559","document":"tm221771-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922001559/tm221771-6_4seq1.xml","form_type":"4"}},{"id":2448013,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-01-04T21:20:27.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":9500,"price":2.5,"value":23750.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued to the Reporting Person pursuant to his election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $23,750 for Board services for the fourth fiscal quarter of 2021.  The shares were issued on the last day of the fourth fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter."}],"balance_after":178685,"source":{"system":"sec-edgar","filing":"0000899243-22-000502","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000089924322000502/doc4.xml","form_type":"4"}},{"id":2554119,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2021-10-01T20:30:41.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":4640,"price":5.12,"value":23756.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued to the Reporting Person pursuant to his election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $23,750 for Board services for the third fiscal quarter of 2021.  The shares were issued on the last day of the third fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter."}],"balance_after":169185,"source":{"system":"sec-edgar","filing":"0000899243-21-038635","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000089924321038635/doc4.xml","form_type":"4"}},{"id":2560252,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-24T21:10:12.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":1200,"price":255.3835,"value":306460.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $255.11 to $255.60, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001209191-21-057658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121057658/doc4.xml","form_type":"4"}},{"id":2560251,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-24T21:10:12.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":2732,"price":254.4631,"value":695193.1892,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.06 to $255.05, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":41200,"source":{"system":"sec-edgar","filing":"0001209191-21-057658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121057658/doc4.xml","form_type":"4"}},{"id":2560250,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-24T21:10:12.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":7744,"price":253.4614,"value":1962805.0816,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $253.00 to $253.97, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":43932,"source":{"system":"sec-edgar","filing":"0001209191-21-057658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121057658/doc4.xml","form_type":"4"}},{"id":2560249,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-24T21:10:12.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":7557,"price":252.5589,"value":1908587.6073,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $251.98 to $252.91, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":51676,"source":{"system":"sec-edgar","filing":"0001209191-21-057658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121057658/doc4.xml","form_type":"4"}},{"id":2560248,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-24T21:10:12.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":5728,"price":251.3216,"value":1439570.1248,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.92 to $251.87, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":59233,"source":{"system":"sec-edgar","filing":"0001209191-21-057658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121057658/doc4.xml","form_type":"4"}},{"id":2643959,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2021-07-02T21:01:30.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":579494,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount"}],"balance_after":579494,"derivative":{"exercise_price":0.71,"exercise_date":"2022-07-01","expiration_date":"2031-07-01","underlying":"Ordinary Shares","underlying_shares":579494},"source":{"system":"sec-edgar","filing":"0001104659-21-088965","document":"tm2121284-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000110465921088965/tm2121284-2_4seq1.xml","form_type":"4"}},{"id":2647326,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2021-07-01T20:15:28.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":2858,"price":8.31,"value":23749.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued to the Reporting Person pursuant to his election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $23,750 for Board services for the second fiscal quarter of 2021.  The shares were issued on the last day of the second fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter."}],"balance_after":164545,"source":{"system":"sec-edgar","filing":"0000899243-21-026955","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219871/000089924321026955/doc4.xml","form_type":"4"}},{"id":2650066,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-30T21:29:54.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":7728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest on the first anniversary of the date of grant or, if earlier, the date of Imara's next annual meeting of stockholders following the date of grant."}],"balance_after":7728,"derivative":{"exercise_price":8.12,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":7728},"source":{"system":"sec-edgar","filing":"0001209191-21-044007","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000120919121044007/doc4.xml","form_type":"4"}},{"id":2659502,"issuer":{"id":4632,"kind":"organization","name":"NOVAVAX INC"},"owners":[{"id":36116,"kind":"person","name":"MOTT DAVID M","position":1,"cik":"0001219871","reported_name":"MOTT DAVID M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-22T21:20:45.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Company common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date."}],"balance_after":700,"derivative":{"underlying":"Common Stock","underlying_shares":700},"source":{"system":"sec-edgar","filing":"0001209191-21-042458","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1000694/000120919121042458/doc4.xml","form_type":"4"}}],"next_cursor":"2021-06-22T21:20:45.000000Z,2659502"}